[
  {
    "brand_name": "Abecma",
    "hcpcs_code": "Q2055",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "No",
    "indication": "Multiple myeloma",
    "indicated_population": "MM (RR, TCE, atleast two prior lines)",
    "label_population": "Abecma is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Authorization is granted for 3 months, and specific criteria related to prior treatments, ECOG performance status, organ function, and absence of CNS involvement, active infection, or inflammatory disorders must be met.",
    "clinical_criteria": "Authorization of 3 months may be granted for treatment of relapsed or refractory multiple myeloma in members 18 years of age and older when all of the following criteria are met:\nA. The member has received prior treatment with at least two lines of therapy, including at least one drug from each of the following categories:\n1. Immunomodulatory agent\n2. Proteasome inhibitor\n3. Anti-CD38 monoclonal antibody\nB. The member has not received a previous treatment course of the requested medication or another CAR-T therapy directed at any target.\nC. The member has an ECOG performance status of 0 to 2.\nD. The member has adequate and stable kidney, liver, and cardiac function.\nE. The member does not have known active or prior history of central nervous system (CNS) involvement (e.g., CNS multiple myeloma)\nF. The member does not have clinically significant active infection.\nG. The member does not have an active inflammatory disorder.",
    "exclusion_criteria": "The member has not received a previous treatment course of the requested medication or another CAR-T therapy directed at any target. The member does not have known active or prior history of central nervous system (CNS) involvement (e.g., CNS multiple myeloma). The member does not have clinically significant active infection. The member does not have an active inflammatory disorder.",
    "evidence_rationale": "The prescribing information for Abecma. The available compendium a. National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium b. Micromedex DrugDex c. American Hospital Formulary Service- Drug Information (AHFS-DI) d. Lexi-Drugs e. Clinical Pharmacology. NCCN Guideline: Multiple myeloma. National Coverage Determination: Chimeric Antigen Receptor (CAR) T-cell Therapy",
    "continuation_of_therapy": "Not mentioned",
    "plan_type": "Commercial, medicare",
    "policy_revised_date": "2024-09-26 00:00:00",
    "policy_effective_date": "2024-11-01 00:00:00",
    "policy_approved_date": "2024-09-26 00:00:00",
    "prior_authorization_summary": "",
    "preferred_products": "",
    "exception_criteria": "",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Abecma-4643-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Adakveo",
    "hcpcs_code": "J0791",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "No",
    "indication": "Sickle-cell syndrome",
    "indicated_population": "Sickle-cell syndrome (in prevention of recurrent painful vaso-occlusive crises, in 16 years and older)",
    "label_population": "Adakveo is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in members 16 years of age or older with sickle cell disease. Authorization requires at least one VOC in the prior 12 months and specific sickle cell disease genotypes or a history of inadequate response, intolerance, or contraindication to hydroxyurea. Concurrent use with hydroxyurea is also considered.",
    "clinical_criteria": "Authorization of 12 months may be granted for use in reducing the frequency of vaso-occlusive crises (VOCs) in members 16 years of age or older with sickle cell disease when both of the following criteria are met:\n• The member has experienced at least one vaso-occlusive crisis within the previous 12 months.\n• The member meets either of the following:\n Member has sickle hemoglobin C (HbSC), sickle β+-thalassemia (HbSβ+), or other genotypic variants of sickle cell disease (e.g., HbS-O Arab, HbS-Lepore).\n Member has homozygous hemoglobin S (HbSS) or sickle β0-thalassemia (HbSβ0) genotype AND meets any of the following:\n• Has experienced, at any time in the past, an inadequate response or intolerance to a trial of hydroxyurea\n• Has a contraindication to hydroxyurea\n• Will be using Adakveo with concurrent hydroxyurea therapy",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "The prescribing information for Adakveo; National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium; Micromedex DrugDex; American Hospital Formulary Service- Drug Information (AHFS-DI); Lexi-Drugs; Clinical Pharmacology; Evidence-based management of Sickle Cell Disease (NHLBI); Guidelines for the use of hydroxycarbamide in children and adults (2018 British Society for Haematology); Hydroxyurea (hydroxycarbamide) for sickle cell disease (Cochrane Review)",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met:\n• The member is currently receiving therapy with Adakveo.\n• Adakveo is being used to treat an indication listed in the coverage criteria section.\n• The member is receiving benefit from therapy. Benefit is defined as reduction in the frequency of vaso-occlusive crises, or maintenance of such reduction, since initiating therapy with Adakveo.",
    "plan_type": "Commercial, medicare",
    "policy_revised_date": "2025-02-01 00:00:00",
    "policy_effective_date": "2025-05-01 00:00:00",
    "policy_approved_date": "2025-03-27 00:00:00",
    "prior_authorization_summary": "Yes, Precertification of crizanlizumab-tmca (Adakveo) is required of all Aetna participating providers and members in applicable plan designs. Call (866) 752-7021 or fax (888) 267-3277.",
    "preferred_products": "",
    "exception_criteria": "",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Adakveo-3416-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Adzynma",
    "hcpcs_code": "J7171",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "No",
    "indication": "Thrombotic Thrombocytopenic Purpura",
    "indicated_population": "TTP (congenital, prophylactic or on-demand ERT)",
    "label_population": "Adzynma is indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). Initial approval requires confirmation of cTTP diagnosis via genetic testing and an ADAMTS13 activity level of less than 10%.",
    "clinical_criteria": "Authorization of 6 months may be granted for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) when both of the following criteria are met:\nA. The diagnosis of cTTP has been confirmed by genetic testing with biallelic mutations in the ADAMTS13 gene.\nB. Member has an ADAMTS13 activity level of less than 10% at the time of diagnosis.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "Support for using an enzyme assay and genetic testing to confirm the diagnosis of cTTP prior to initiating treatment with Adzynma can be found in the clinical trials cited in the prescribing information. To be included in the trial, the patient must have had a documented diagnosis of severe hereditary ADAMTS13 deficiency, defined as: A) Confirmed by molecular genetic testing, documented in participant history or at screening, and B) ADAMTS13 activity < 10 % as measured by the fluorescent resonance energy transfer- von Willebrand factor73 (FRETS-VWF73) assay, documented in participant history or at screening (participants currently receiving standard of care prophylactic therapy may exceed 10% ADAMTS13 activity at screening). Additionally, an article from The New England Journal of Medicine, cited in the prescribing information, indicates that hereditary TTP is caused by biallelic mutations in the gene ADAMTS13 that lead to a severe ADAMTS13 deficiency (ADAMTS13 activity <10% of that in normal plasma).",
    "continuation_of_therapy": "Authorization of 12 months may be granted for continued treatment of congenital thrombotic thrombocytopenic purpura (cTTP) when both of the following criteria are met:\nA. The member is currently receiving therapy with the requested medication.\nB. The member is receiving benefit from therapy (e.g., reduction or maintenance of number of thrombotic thrombocytopenic purpura [TTP] events, increase in platelet count, decrease in lactate dehydrogenase [LDH] level).",
    "plan_type": "Commercial, medicare",
    "policy_revised_date": "2024-02-01 00:00:00",
    "policy_effective_date": "2024-04-01 00:00:00",
    "policy_approved_date": "2024-02-29 00:00:00",
    "prior_authorization_summary": "",
    "preferred_products": "",
    "exception_criteria": "",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Adzynma-6251-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Alymsys",
    "hcpcs_code": "Q5126",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Colorectal cancer",
    "indicated_population": "CRC (met, naïve)",
    "label_population": "Alymsys, in combination with specific chemotherapy regimens, is indicated for first- or second-line treatment of metastatic colorectal cancer. Coverage is authorized for 12 months, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence supporting this indication includes FDA approval, NCCN guidelines, and Medicare policies.",
    "clinical_criteria": "Authorization of 12 months may be granted for treatment of colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma. Alymsys, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer. Alymsys in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab-containing regimen.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "FDA-Approved Indications, NCCN Drugs & Biologics Compendium, Micromedex DrugDex, NCCN Guideline: Colon Cancer, NCCN Guideline: Rectal Cancer, NCCN Guideline: Anal Carcinoma, National Coverage Determination (NCD) for Anti-cancer Chemotherapy for Colorectal Cancer (110.17)",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met: The member is currently receiving therapy with the requested medication. The requested medication is being used to treat an indication in the coverage criteria section (excluding central nervous system necrosis due to exposure to ionizing radiation). The member is receiving benefit from therapy. Benefit is defined as: No evidence of unacceptable toxicity while on the current regimen and No evidence of disease progression while on the current regimen.",
    "plan_type": "Medicare",
    "policy_revised_date": "2025-05-01 00:00:00",
    "policy_effective_date": "2025-07-01 00:00:00",
    "policy_approved_date": "2025-05-29 00:00:00",
    "prior_authorization_summary": "This is an Aetna Medicare Part B Drug Criteria policy document focusing on Avastin and bevacizumab biosimilars, including Alymsys (bevacizumab-maly), for oncology. The policy provides coverage criteria for FDA-approved indications of Alymsys, which include metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The policy covers on-label uses of Alymsys. Authorization for 12 months may be granted for these indications, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence base includes FDA prescribing information and NCCN guidelines. The policy was revised in May 2025 and is effective from July 1, 2025.",
    "preferred_products": "Mvasi (bevacizumab-awwb); Zirabev (bevacizumab-bvzr)",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member; 5. The request is for a medically necessary indication not listed above",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Avastin-and-bevacizumab-biosimilars-Oncology-2477-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Alymsys",
    "hcpcs_code": "Q5126",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Colorectal cancer",
    "indicated_population": "CRC (met, 2nd line, in combi with CT)",
    "label_population": "Alymsys, in combination with specific chemotherapy regimens, is indicated for first- or second-line treatment of metastatic colorectal cancer. Coverage is authorized for 12 months, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence supporting this indication includes FDA approval, NCCN guidelines, and Medicare policies.",
    "clinical_criteria": "Authorization of 12 months may be granted for treatment of colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma. Alymsys, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer. Alymsys in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab-containing regimen.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "FDA-Approved Indications, NCCN Drugs & Biologics Compendium, Micromedex DrugDex, NCCN Guideline: Colon Cancer, NCCN Guideline: Rectal Cancer, NCCN Guideline: Anal Carcinoma, National Coverage Determination (NCD) for Anti-cancer Chemotherapy for Colorectal Cancer (110.17)",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met: The member is currently receiving therapy with the requested medication. The requested medication is being used to treat an indication in the coverage criteria section (excluding central nervous system necrosis due to exposure to ionizing radiation). The member is receiving benefit from therapy. Benefit is defined as: No evidence of unacceptable toxicity while on the current regimen and No evidence of disease progression while on the current regimen.",
    "plan_type": "Medicare",
    "policy_revised_date": "2025-05-01 00:00:00",
    "policy_effective_date": "2025-07-01 00:00:00",
    "policy_approved_date": "2025-05-29 00:00:00",
    "prior_authorization_summary": "This is an Aetna Medicare Part B Drug Criteria policy document focusing on Avastin and bevacizumab biosimilars, including Alymsys (bevacizumab-maly), for oncology. The policy provides coverage criteria for FDA-approved indications of Alymsys, which include metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The policy covers on-label uses of Alymsys. Authorization for 12 months may be granted for these indications, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence base includes FDA prescribing information and NCCN guidelines. The policy was revised in May 2025 and is effective from July 1, 2025.",
    "preferred_products": "Mvasi (bevacizumab-awwb); Zirabev (bevacizumab-bvzr)",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member; 5. The request is for a medically necessary indication not listed above",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Avastin-and-bevacizumab-biosimilars-Oncology-2477-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Alymsys",
    "hcpcs_code": "Q5126",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Colorectal cancer",
    "indicated_population": "CRC (met, 2nd line)",
    "label_population": "Alymsys, in combination with specific chemotherapy regimens, is indicated for first- or second-line treatment of metastatic colorectal cancer. Coverage is authorized for 12 months, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence supporting this indication includes FDA approval, NCCN guidelines, and Medicare policies.",
    "clinical_criteria": "Authorization of 12 months may be granted for treatment of colorectal cancer, including appendiceal adenocarcinoma and anal adenocarcinoma. Alymsys, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer. Alymsys in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab-containing regimen.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "FDA-Approved Indications, NCCN Drugs & Biologics Compendium, Micromedex DrugDex, NCCN Guideline: Colon Cancer, NCCN Guideline: Rectal Cancer, NCCN Guideline: Anal Carcinoma, National Coverage Determination (NCD) for Anti-cancer Chemotherapy for Colorectal Cancer (110.17)",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met: The member is currently receiving therapy with the requested medication. The requested medication is being used to treat an indication in the coverage criteria section (excluding central nervous system necrosis due to exposure to ionizing radiation). The member is receiving benefit from therapy. Benefit is defined as: No evidence of unacceptable toxicity while on the current regimen and No evidence of disease progression while on the current regimen.",
    "plan_type": "Medicare",
    "policy_revised_date": "2025-05-01 00:00:00",
    "policy_effective_date": "2025-07-01 00:00:00",
    "policy_approved_date": "2025-05-29 00:00:00",
    "prior_authorization_summary": "This is an Aetna Medicare Part B Drug Criteria policy document focusing on Avastin and bevacizumab biosimilars, including Alymsys (bevacizumab-maly), for oncology. The policy provides coverage criteria for FDA-approved indications of Alymsys, which include metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The policy covers on-label uses of Alymsys. Authorization for 12 months may be granted for these indications, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence base includes FDA prescribing information and NCCN guidelines. The policy was revised in May 2025 and is effective from July 1, 2025.",
    "preferred_products": "Mvasi (bevacizumab-awwb); Zirabev (bevacizumab-bvzr)",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member; 5. The request is for a medically necessary indication not listed above",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Avastin-and-bevacizumab-biosimilars-Oncology-2477-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Alymsys",
    "hcpcs_code": "Q5126",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (non-squamous, met, naïve)",
    "label_population": "Alymsys, when used in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of non-squamous non-small cell lung cancer. Coverage is authorized for 12 months, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. This indication is supported by FDA approval and NCCN guidelines.",
    "clinical_criteria": "Authorization of 12 months may be granted for treatment of symptomatic local, recurrent, unresectable, advanced or metastatic non-squamous non-small cell lung cancer. Alymsys, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "FDA-Approved Indications, NCCN Drugs & Biologics Compendium, NCCN Guideline: Non-small cell lung cancer",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met: The member is currently receiving therapy with the requested medication. The requested medication is being used to treat an indication in the coverage criteria section (excluding central nervous system necrosis due to exposure to ionizing radiation). The member is receiving benefit from therapy. Benefit is defined as: No evidence of unacceptable toxicity while on the current regimen and No evidence of disease progression while on the current regimen.",
    "plan_type": "Medicare",
    "policy_revised_date": "2025-05-01 00:00:00",
    "policy_effective_date": "2025-07-01 00:00:00",
    "policy_approved_date": "2025-05-29 00:00:00",
    "prior_authorization_summary": "This is an Aetna Medicare Part B Drug Criteria policy document focusing on Avastin and bevacizumab biosimilars, including Alymsys (bevacizumab-maly), for oncology. The policy provides coverage criteria for FDA-approved indications of Alymsys, which include metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The policy covers on-label uses of Alymsys. Authorization for 12 months may be granted for these indications, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence base includes FDA prescribing information and NCCN guidelines. The policy was revised in May 2025 and is effective from July 1, 2025.",
    "preferred_products": "Mvasi (bevacizumab-awwb); Zirabev (bevacizumab-bvzr)",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member; 5. The request is for a medically necessary indication not listed above",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Avastin-and-bevacizumab-biosimilars-Oncology-2477-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Alymsys",
    "hcpcs_code": "Q5126",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Glioblastoma",
    "indicated_population": "Glioblastoma (2nd line)",
    "label_population": "Alymsys is indicated for the treatment of recurrent glioblastoma in adults. Coverage is authorized for 12 months, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. This indication is supported by FDA approval.",
    "clinical_criteria": "Alymsys is indicated for the treatment of recurrent glioblastoma in adults.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "FDA-Approved Indications",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met: The member is currently receiving therapy with the requested medication. The requested medication is being used to treat an indication in the coverage criteria section (excluding central nervous system necrosis due to exposure to ionizing radiation). The member is receiving benefit from therapy. Benefit is defined as: No evidence of unacceptable toxicity while on the current regimen and No evidence of disease progression while on the current regimen.",
    "plan_type": "Medicare",
    "policy_revised_date": "2025-05-01 00:00:00",
    "policy_effective_date": "2025-07-01 00:00:00",
    "policy_approved_date": "2025-05-29 00:00:00",
    "prior_authorization_summary": "This is an Aetna Medicare Part B Drug Criteria policy document focusing on Avastin and bevacizumab biosimilars, including Alymsys (bevacizumab-maly), for oncology. The policy provides coverage criteria for FDA-approved indications of Alymsys, which include metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The policy covers on-label uses of Alymsys. Authorization for 12 months may be granted for these indications, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence base includes FDA prescribing information and NCCN guidelines. The policy was revised in May 2025 and is effective from July 1, 2025.",
    "preferred_products": "Mvasi (bevacizumab-awwb); Zirabev (bevacizumab-bvzr)",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member; 5. The request is for a medically necessary indication not listed above",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Avastin-and-bevacizumab-biosimilars-Oncology-2477-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Alymsys",
    "hcpcs_code": "Q5126",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Renal cell carcinoma",
    "indicated_population": "RCC (met, naïve)",
    "label_population": "Alymsys, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma. Coverage is authorized for 12 months, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. This indication is supported by FDA approval and NCCN guidelines.",
    "clinical_criteria": "Authorization of 12 months may be granted for treatment of relapsed or stage IV renal cell cancer. Alymsys, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell carcinoma.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "FDA-Approved Indications, NCCN Drugs & Biologics Compendium, NCCN Guideline: Kidney cancer",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met: The member is currently receiving therapy with the requested medication. The requested medication is being used to treat an indication in the coverage criteria section (excluding central nervous system necrosis due to exposure to ionizing radiation). The member is receiving benefit from therapy. Benefit is defined as: No evidence of unacceptable toxicity while on the current regimen and No evidence of disease progression while on the current regimen.",
    "plan_type": "Medicare",
    "policy_revised_date": "2025-05-01 00:00:00",
    "policy_effective_date": "2025-07-01 00:00:00",
    "policy_approved_date": "2025-05-29 00:00:00",
    "prior_authorization_summary": "This is an Aetna Medicare Part B Drug Criteria policy document focusing on Avastin and bevacizumab biosimilars, including Alymsys (bevacizumab-maly), for oncology. The policy provides coverage criteria for FDA-approved indications of Alymsys, which include metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The policy covers on-label uses of Alymsys. Authorization for 12 months may be granted for these indications, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence base includes FDA prescribing information and NCCN guidelines. The policy was revised in May 2025 and is effective from July 1, 2025.",
    "preferred_products": "Mvasi (bevacizumab-awwb); Zirabev (bevacizumab-bvzr)",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member; 5. The request is for a medically necessary indication not listed above",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Avastin-and-bevacizumab-biosimilars-Oncology-2477-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Alymsys",
    "hcpcs_code": "Q5126",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Cervical cancer",
    "indicated_population": "Cervical cancer (met, CT IT)",
    "label_population": "Alymsys, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer. Coverage is authorized for 12 months, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. This indication is supported by FDA approval and NCCN guidelines.",
    "clinical_criteria": "Authorization of 12 months may be granted for treatment of persistent, recurrent, or metastatic cervical cancer. Alymsys, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "FDA-Approved Indications, NCCN Drugs & Biologics Compendium, NCCN Guideline: Cervical cancer",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met: The member is currently receiving therapy with the requested medication. The requested medication is being used to treat an indication in the coverage criteria section (excluding central nervous system necrosis due to exposure to ionizing radiation). The member is receiving benefit from therapy. Benefit is defined as: No evidence of unacceptable toxicity while on the current regimen and No evidence of disease progression while on the current regimen.",
    "plan_type": "Medicare",
    "policy_revised_date": "2025-05-01 00:00:00",
    "policy_effective_date": "2025-07-01 00:00:00",
    "policy_approved_date": "2025-05-29 00:00:00",
    "prior_authorization_summary": "This is an Aetna Medicare Part B Drug Criteria policy document focusing on Avastin and bevacizumab biosimilars, including Alymsys (bevacizumab-maly), for oncology. The policy provides coverage criteria for FDA-approved indications of Alymsys, which include metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The policy covers on-label uses of Alymsys. Authorization for 12 months may be granted for these indications, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence base includes FDA prescribing information and NCCN guidelines. The policy was revised in May 2025 and is effective from July 1, 2025.",
    "preferred_products": "Mvasi (bevacizumab-awwb); Zirabev (bevacizumab-bvzr)",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member; 5. The request is for a medically necessary indication not listed above",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Avastin-and-bevacizumab-biosimilars-Oncology-2477-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Alymsys",
    "hcpcs_code": "Q5126",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Ovarian cancer",
    "indicated_population": "Ovarian, Peritoneal, Fallopian tube cancer (in combi with CT, 2nd line)",
    "label_population": "Alymsys, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Coverage is authorized for 12 months, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. This indication is supported by FDA approval and NCCN guidelines.",
    "clinical_criteria": "Authorization of 12 months may be granted for treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and malignant sex cord stromal tumors. Alymsys, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "FDA-Approved Indications, NCCN Drugs & Biologics Compendium, NCCN Guideline: Ovarian cancer, including fallopian tube cancer and primary peritoneal cancer",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met: The member is currently receiving therapy with the requested medication. The requested medication is being used to treat an indication in the coverage criteria section (excluding central nervous system necrosis due to exposure to ionizing radiation). The member is receiving benefit from therapy. Benefit is defined as: No evidence of unacceptable toxicity while on the current regimen and No evidence of disease progression while on the current regimen.",
    "plan_type": "Medicare",
    "policy_revised_date": "2025-05-01 00:00:00",
    "policy_effective_date": "2025-07-01 00:00:00",
    "policy_approved_date": "2025-05-29 00:00:00",
    "prior_authorization_summary": "This is an Aetna Medicare Part B Drug Criteria policy document focusing on Avastin and bevacizumab biosimilars, including Alymsys (bevacizumab-maly), for oncology. The policy provides coverage criteria for FDA-approved indications of Alymsys, which include metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. The policy covers on-label uses of Alymsys. Authorization for 12 months may be granted for these indications, contingent on the patient's ongoing benefit from the therapy and absence of unacceptable toxicity or disease progression. The evidence base includes FDA prescribing information and NCCN guidelines. The policy was revised in May 2025 and is effective from July 1, 2025.",
    "preferred_products": "Mvasi (bevacizumab-awwb); Zirabev (bevacizumab-bvzr)",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member; 5. The request is for a medically necessary indication not listed above",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Avastin-and-bevacizumab-biosimilars-Oncology-2477-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Amvuttra",
    "hcpcs_code": "J0225",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "No",
    "indication": "Amyloidosis",
    "indicated_population": "hATTR amyloidosis (polyneuropathy, in adults)",
    "label_population": "Amvuttra is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Coverage requires confirmation of a TTR gene mutation and clinical manifestations of ATTR-FAP, and the patient must not be a liver transplant recipient or using other ATTR-FAP medications. Continuation of therapy requires demonstrated clinical benefit compared to baseline.",
    "clinical_criteria": "Authorization of 12 months may be granted for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (also called transthyretin-type familial amyloid polyneuropathy [ATTR-FAP]) when all of the following criteria are met:\n• The diagnosis is confirmed by detection of a mutation in the TTR gene.\n• Member exhibits clinical manifestations of ATTR-FAP (e.g., amyloid deposition in biopsy specimens, TTR protein variants in serum, progressive peripheral sensory-motor polyneuropathy).\n• Member is not a liver transplant recipient.\n• The requested medication will not be used in combination with any other medication approved for the treatment of hereditary transthyretin-mediated amyloidosis (e.g., Onpattro, Tegsedi, Vyndamax, Vyndaqel, Wainua).",
    "exclusion_criteria": "Member is a liver transplant recipient. The requested medication will be used in combination with any other medication approved for the treatment of hereditary transthyretin-mediated amyloidosis (e.g., Onpattro, Tegsedi, Vyndamax, Vyndaqel, Wainua).",
    "evidence_rationale": "FDA-approved indications listed in the prescribing information for Amvuttra are covered. Support for using the initial criteria can be found in a guideline from Ando and colleagues and a Gene Reviews chapter discussing hereditary transthyretin amyloidosis.",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met:\n• The member is currently receiving treatment with the requested medication.\n• The requested medication is being used to treat an indication enumerated in the coverage criteria section.\n• There is a clinical benefit from therapy with the requested medication compared to baseline (e.g., improvement of neuropathy severity and rate of disease progression as demonstrated by the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score, the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score, polyneuropathy disability (PND) score, FAP disease stage, manual grip strength).",
    "plan_type": "Commercial, medicare",
    "policy_revised_date": "2025-01-01 00:00:00",
    "policy_effective_date": "2025-04-01 00:00:00",
    "policy_approved_date": "2025-02-27 00:00:00",
    "prior_authorization_summary": "",
    "preferred_products": "",
    "exception_criteria": "",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Amvuttra-5499-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Axtle",
    "hcpcs_code": "J9292",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (non-squamous, met, naive in combi with cisplatin)",
    "label_population": "Axtle is a folate analog metabolic inhibitor indicated:\n• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.\n• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n• as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.",
    "clinical_criteria": "All indication in FDA",
    "exclusion_criteria": "Pemetrexed is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer (NSCLC).",
    "evidence_rationale": "",
    "continuation_of_therapy": "",
    "plan_type": "Medicare",
    "policy_revised_date": "",
    "policy_effective_date": "",
    "policy_approved_date": "",
    "prior_authorization_summary": "",
    "preferred_products": "Alimta; Pemetrexed",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Pemetrexed-products-6298-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Axtle",
    "hcpcs_code": "J9292",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (non-squamous, maintenance Tx, no progression post 1L pt CT)",
    "label_population": "Axtle is a folate analog metabolic inhibitor indicated:\n• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.\n• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n• as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.",
    "clinical_criteria": "All indication in FDA",
    "exclusion_criteria": "Pemetrexed is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer (NSCLC).",
    "evidence_rationale": "",
    "continuation_of_therapy": "",
    "plan_type": "Medicare",
    "policy_revised_date": "",
    "policy_effective_date": "",
    "policy_approved_date": "",
    "prior_authorization_summary": "",
    "preferred_products": "Alimta; Pemetrexed",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Pemetrexed-products-6298-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Axtle",
    "hcpcs_code": "J9292",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "Yes",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (non-squamous, recurrent, met, post CT)",
    "label_population": "Axtle is a folate analog metabolic inhibitor indicated:\n• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC.\n• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n• as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.",
    "clinical_criteria": "All indication in FDA",
    "exclusion_criteria": "Pemetrexed is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer (NSCLC).",
    "evidence_rationale": "",
    "continuation_of_therapy": "",
    "plan_type": "Medicare",
    "policy_revised_date": "",
    "policy_effective_date": "",
    "policy_approved_date": "",
    "prior_authorization_summary": "",
    "preferred_products": "Alimta; Pemetrexed",
    "exception_criteria": "1. Member has received the requested product in the past 365 days; 2. Inadequate response to a trial of one or more of the preferred products; 3. Intolerable adverse event to one or more of the preferred products; 4. The preferred products are contraindicated for the member",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Pemetrexed-products-6298-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Eligard",
    "hcpcs_code": "J9217",
    "prior_authorization_required": "No",
    "step_therapy_required": "No",
    "indication": "Prostate cancer",
    "indicated_population": "Prostate cancer (advanced)",
    "label_population": "Eligard is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.",
    "clinical_criteria": "",
    "exclusion_criteria": "Not available",
    "evidence_rationale": "",
    "continuation_of_therapy": "",
    "plan_type": "Medicare",
    "policy_revised_date": "",
    "policy_effective_date": "",
    "policy_approved_date": "",
    "prior_authorization_summary": "",
    "preferred_products": "",
    "exception_criteria": "",
    "link": "",
    "insurer": "Aetna"
  },
  {
    "brand_name": "Elrexfio",
    "hcpcs_code": "J1323",
    "prior_authorization_required": "Yes",
    "step_therapy_required": "No",
    "indication": "Multiple myeloma",
    "indicated_population": "MM (RR, TCE, atleast four prior lines)",
    "label_population": "Elrexfio is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.",
    "clinical_criteria": "Authorization of 12 months may be granted for treatment of relapsed or refractory multiple myeloma in members who have received at least 4 prior therapies, including at least one drug from each of the following categories:\n1. Anti-CD38 monoclonal antibody (e.g., daratumumab)\n2. Proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib)\n3. Immunomodulatory agent (e.g., lenalidomide, pomalidomide)",
    "exclusion_criteria": "No exclusions",
    "evidence_rationale": "The prescribing information for Elrexfio.",
    "continuation_of_therapy": "Authorization for 12 months may be granted when all of the following criteria are met:\n1. The member is currently receiving therapy with the requested medication\n2. The requested medication is being used to treat an indication enumerated in Section II\n3. The member is receiving benefit from therapy. Benefit is defined as:\ni. No evidence of unacceptable toxicity while on the current regimen AND\nii. No evidence of disease progression while on the current regimen",
    "plan_type": "Commercial, medicare",
    "policy_revised_date": "2023-11-01 00:00:00",
    "policy_effective_date": "",
    "policy_approved_date": "2023-11-01 00:00:00",
    "prior_authorization_summary": "",
    "preferred_products": "",
    "exception_criteria": "",
    "link": "https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/healthcare-professionals/documents-forms/Elrexfio-6121-A-Aetna-MedB.pdf",
    "insurer": "Aetna"
  }
]